The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
To evaluate the efiicacy of TAI combine SBRT in unresectable HCC
Hepatocellular Carcinoma
COMBINATION_PRODUCT: TAI combine SBRT
PFS, progression-free survival, From date of randomization until the date of progression, assessed up to 36 months|ORR, objective response rate, From date of randomization until the date of death, assessed up to 36 months
OS, overall survival, From date of randomization until the date of death from any cause, assessed up to 36 months|DCR, disease control rate, From date of randomization until the date of death, assessed up to 36 months
To evaluate the efiicacy of TAI combine SBRT in unresectable HCC